These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37867604)

  • 21. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
    Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
    Dimou M; Papageorgiou SG; Stavroyianni N; Katodritou E; Tsirogianni M; Kalpadakis C; Banti A; Arapaki M; Iliakis T; Bouzani M; Verrou E; Spanoudakis E; Giannouli S; Marinakis T; Mandala E; Mparmparousi D; Sachanas S; Dalekou-Tsolakou M; Hatzimichael E; Vadikolia C; Violaki V; Poziopoulos C; Tsirkinidis P; Chatzileontiadou S; Vervessou E; Ximeri M; Sioni A; Konstantinidou P; Kyrtsonis MC; Siakantaris MP; Angelopoulou MK; Pappa V; Konstantopoulos K; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2021 Aug; 39(3):336-348. PubMed ID: 33583077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
    Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D
    Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
    Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
    Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
    Choi Y; Diefenbach CS
    Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma.
    Yasuda H; Kaga N; Taka H; Ochiai T; Yamana T; Miura Y; Ishii M; Sasaki M; Ando J; Ando M
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):265-268. PubMed ID: 37750932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
    Dal MS; Ulu BU; Uzay A; Akay OM; Beşışık S; Yenerel MN; Çelik S; Kaynar L; Yücel OK; Deveci B; Sönmez M; Mehtap Ö; Beköz HS; Sunu C; Salim O; Ulaş T; Kartı S; Altuntaş F; Ferhanoğlu B; Tuğlular TF
    Ann Hematol; 2023 Jan; 102(1):133-140. PubMed ID: 36401621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
    Kawasaki N; Nishito Y; Yoshimura Y; Yoshiura S
    Br J Haematol; 2022 Oct; 199(2):245-255. PubMed ID: 35764309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Lu T; Gibiansky L; Li X; Li C; Shi R; Agarwal P; Hirata J; Miles D; Chanu P; Girish S; Jin JY; Lu D
    Leuk Lymphoma; 2020 Dec; 61(12):2905-2914. PubMed ID: 32705923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
    Wang YW; Tsai XC; Hou HA; Tien FM; Liu JH; Chou WC; Ko BS; Chen YW; Lin CC; Cheng CL; Lo MY; Lin YC; Lu LC; Wu SJ; Kuo SH; Hong RL; Huang TC; Yao M
    Ann Hematol; 2022 Feb; 101(2):349-358. PubMed ID: 34766217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Shi R; Lu T; Ku G; Ding H; Saito T; Gibiansky L; Agarwal P; Li X; Jin JY; Girish S; Miles D; Li C; Lu D
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):347-359. PubMed ID: 32770353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
    Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.
    Eslami M; Mehrabi M; Payandeh M; Saba F
    PLoS One; 2024; 19(8):e0308247. PubMed ID: 39088571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
    Tarantelli C; Bertoni F
    Br J Haematol; 2022 Oct; 199(2):169-170. PubMed ID: 35917107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
    Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnňný M; Musick L; Hirata J; Yang A; Sehn LH
    Haematologica; 2024 Apr; 109(4):1194-1205. PubMed ID: 37767550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
    Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
    J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
    [No Abstract]   [Full Text] [Related]  

  • 39. Central nervous system relapse after combination therapy including polatuzumab vedotin in patients with diffuse large B-cell lymphoma.
    Hori Y; Hosoi H; Mushino T; Okabe Y; Sakaki A; Yoshida K; Tochino Y; Yamashita Y; Sonoki T
    Leuk Res Rep; 2024; 21():100467. PubMed ID: 38939513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
    Patel KK; Isufi I; Kothari S; Foss F; Huntington S
    Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.